TickerTain
$SPCX····$NVDA····$MSFT····$GOOGL····$ANTHROPIC·$TSLA····$CRWV····$NBIS····$HIMS····$TSM····$ASML····$FIGURE·$LYFT····$UBER····$SNOW····$META····$ELEVENLABS·$CURSOR·$COGNITION·$OPENAI·$AAPL····$RKLB····$XAI·$AMZN····$AMD····$000660.KS····$INTC····
← newsroom
$MYTHERA · MyThera monthly obesity candidate de-risks post-acquisition with Phase 2 confirmation
now playing · $MYTHERA
$PFE···bullish· high· posalbert bourla
Bourla details $80B acquisition spree and R&D overhaul to drive post-COVID growth
Pfizer invested $80B+ in acquisitions (led by Seagen for ADC tech and MyThera for obesity) while restructuring R&D to improve focus, raising phase 2 success rates from 20% to 50%+…
$SGEN···bullish· high· posalbert bourla
Seagen ADC platform validated as Pfizer's $40B bet pays off with marketed products
Seagen's antibody-drug conjugate (ADC) technology — four marketed products and 13 clinical programs — represents a 'precision missile' approach to cancer therapy that can target m…
$MYTHERAbullish· high· posalbert bourla
MyThera monthly obesity candidate de-risks post-acquisition with Phase 2 confirmation
MyThera's monthly GLP-1 candidate differentiated from weekly competitors (Lilly, Novo) and Phase 2 data confirmed monthly dosing feasibility, validating Pfizer's acquisition thesi…
$1530.HK···neutral· medium· posalbert bourla
Pfizer licenses Chinese innovation via 3SBio deal as early-stage R&D shifts to China
Pfizer is tapping Chinese biotech innovation through licensing deals like 3SBio, but Bourla views this as transitional since Chinese companies will eventually take molecules globa…